Akili (NASDAQ:AKLI) Stock Rating Reaffirmed by Lifesci Capital

Akili (NASDAQ:AKLIGet Rating)‘s stock had its “outperform” rating reiterated by stock analysts at Lifesci Capital in a research report issued to clients and investors on Tuesday, PriceTargets.com reports. Lifesci Capital also issued estimates for Akili’s Q3 2022 earnings at ($0.20) EPS, Q4 2022 earnings at ($0.20) EPS, FY2022 earnings at ($0.85) EPS, Q1 2023 earnings at ($0.20) EPS, Q2 2023 earnings at ($0.19) EPS, Q3 2023 earnings at ($0.19) EPS, Q4 2023 earnings at ($0.19) EPS, FY2023 earnings at ($0.76) EPS, Q1 2024 earnings at ($0.21) EPS, Q2 2024 earnings at ($0.20) EPS and FY2024 earnings at ($0.79) EPS.

A number of other research firms have also commented on AKLI. Cowen initiated coverage on Akili in a report on Tuesday. They issued an “outperform” rating for the company. Cowen started coverage on Akili in a report on Tuesday. They issued an “outperform” rating for the company.

Akili Stock Down 1.8 %

Akili stock opened at $4.47 on Tuesday. Akili has a one year low of $3.73 and a one year high of $37.58.

About Akili

(Get Rating)

Akili, Inc, a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.

Further Reading

Receive News & Ratings for Akili Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akili and related companies with MarketBeat.com's FREE daily email newsletter.